Non-AIDS serious adverse events are as important as AIDS events in patients with advanced multi-drug resistant HIV disease

S T Brown1, J Singer2, A Anis2, T C Kyriakides3, W Cameron4, M Holodniy5, B J Angus6, A Babiker7, K Swanson8, H Sun8
1Bronx VAMC/Mt. Sinai School of Medicine, New York, United States; 2HIV Clinical Trials Network, Vancouver, Canada; 3VA Cooperative Studies Coordinating Center, West Haven, CT, United States; 4Ottawa Hospital, Ottawa, Canada; 5VA Palo Alto, Palo Alto, CA, United States; 6Medical Research Council Clinical Trials Unit/University of Oxford, Oxford, United Kingdom; 7Medical Research Council Clinical Trials Unit, London, United Kingdom; 8VA Cooperative Studies, Albuquerque, NM, United States
Contact e-mail: sheldon.brown@med.va.gov

Background: Both AIDS and non-AIDS events adversely affect clinical outcomes and quality of life (QOL) for HIV+ patients. We compare the type, frequency and QOL consequences of AIDS vs. non-AIDS events in patients having advanced AIDS when treatment options are limited. Methods: OPTIMA is a tri-national trial (UK, Canada, USA) of alternate treatment strategies for patients with advanced HIV disease (CD4 ≤ 300 cells/mm³) and evidence of resistance to 3 classes of antiretroviral (ARV) medications. Groups of patients AIDS-related events (AIDS), non-AIDS serious adverse events (SAE’s), or no serious clinical event were identified. Scores from the Medical Outcomes Study HIV (MOS-HIV) QOL instrument, both physical health status (PHS) and mental health status (MHS), were calculated at baseline, pre-event, and post-event. Concurrent SAE’s and AIDS events and those with missing MOS-HIV data were excluded. Results: As of December 2003, 255 patients were enrolled, median CD4 = 111 cells/mm³, median follow-up = 11 months. Of 23 deaths, 9 were HIV related, 5 unrelated, and 9 to be adjudicated. There were 167 non-AIDS SAE’s in 67 patients and 65 AIDS events in 35 patients, of which 79 were evaluable. There were no differences in pre-event scores between groups. Compared to patients without events, the decrease in PHS scores was greater for SAE’s (p =.006) and the decrease in MHS scores was greater for both SAE’s (p = .013) and AIDS events (p < .003). PHS and MHS declines from pre-event to post-event status did not differ between AIDS events and non-AIDS SAE’s. However, significant decreases in pre-event to post-event scores occurred in PHS following SAE’s (p = .002) and in MHS following AIDS events (p = .033). Conclusion: Non-AIDS SAE’s are more common than AIDS related events in patients with advanced multi-drug resistant HIV. Non-AIDS and AIDS events have comparable serious adverse effects on quality of life in this population.